De Windt, L.J., Lim, H.W., Haq, S., Force, T. & Molkentin, J.D. Calcineurin promotes protein kinase C and c-Jun NH2-terminal kinase activation in the heart. Cross-talk between cardiac hypertrophic signaling pathways. J. Biol. Chem. 275, 13571-13579

Harvard University, Cambridge, Massachusetts, United States
Journal of Biological Chemistry (Impact Factor: 4.57). 06/2000; 275(18):13571-9. DOI: 10.1074/jbc.275.18.13571
Source: PubMed


Multiple intracellular signaling pathways have been shown to regulate the hypertrophic growth of cardiomyocytes. Both necessary and sufficient roles have been described for the mitogen activated protein kinase(1) (MAPK) signaling pathway, specific protein kinase C (PKC) isoforms, and calcineurin. Here we investigate the interdependence between calcineurin, MAPK, and PKC isoforms in regulating cardiomyocyte hypertrophy using three separate approaches. Hearts from hypertrophic calcineurin transgenic mice were characterized for PKC and MAPK activation. Transgenic hearts demonstrated activation of c-Jun NH(2)-terminal kinase (JNK) and extracellular signal-regulated kinase (ERK1/2), but not p38 MAPK factors. Calcineurin transgenic hearts demonstrated increased activation of PKCalpha, beta(1), and theta, but not of epsilon, beta(2), or lambda. In a second approach, cultured cardiomyocytes were infected with a calcineurin adenovirus to induce hypertrophy and the effects of pharmacologic inhibitors or co-infection with a dominant negative adenovirus were examined. Calcineurin-mediated hypertrophy was prevented with PKC inhibitors, Ca(2+) chelation, and attenuated with a dominant negative SEK-1 (MKK4) adenovirus, but inhibitors of ERK or p38 activation had no effect. In a third approach, we examined the activation of MAPK factors and PKC isoforms during the progression of load-induced hypertrophy in aortic banded rats with or without cyclosporine. We determined that inhibition of calcineurin activity with cyclosporine prevented PKCalpha, theta, and JNK activation, but did not affect PKCepsilon, beta, lambda, ERK1/2, or p38 activation. Collectively, these data indicate that calcineurin hypertrophic signaling is interconnected with PKCalpha, theta, and JNK in the heart, while PKCepsilon, beta, lambda, p38, and ERK1/2 are not involved in calcineurin-mediated hypertrophy.

Download full-text


Available from: Hae W Lim, Jun 12, 2014
  • Source
    • "Emerging evidence has shown that excessive mitochondrial ROS production can impair cardiac excitability by affecting the function of various channels and transporters through direct interaction such as posttranslational redox modification of cysteine (S-glutathionylation, sulfhydration, and S-nitrosation) or tyrosine (nitration) residues [17] [18] [19]. Excessive mitochondrial ROS can also modulate ion channel/transporter function indirectly via associated signaling molecules, such as ROS-sensitive kinases, including calcium–calmodulin-dependent protein kinase (CaMKII), cSrc, and protein kinase C (PKC), or via redox-sensitive transcription factors, such as NF-κB [20] [21] [22]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Mitochondria are essential to providing ATP thereby satisfying the energy demand of the incessant electrical activity and contractile action of cardiac muscle. Emerging evidence indicates that mitochondrial dysfunction can adversely impact cardiac electrical functioning by impairing the intracellular ion homeostasis and membrane excitability through reduced ATP production and excessive reactive oxidative species (ROS) generation, resulting in increased propensity to cardiac arrhythmias. In this review, the molecular mechanisms linking mitochondrial dysfunction to cardiac arrhythmias are discussed with an emphasis on the impact of increased mitochondrial ROS on the cardiac ion channels and transporters that are critical to maintaining normal electromechanical functioning of the cardiomyocytes. The potential of using mitochondria-targeted antioxidants as a novel anti-arrhythmia therapy is highlighted.
    Free Radical Biology and Medicine 04/2014; 71. DOI:10.1016/j.freeradbiomed.2014.03.033 · 5.74 Impact Factor
  • Source
    • "Primary culture of neonatal rat cardiomyocytes was carried out as described previously (De Windt et al., 2000). More than 90% of cells were identified as cardiomyocytes by the detection of ␣-actin protein in the cells stained with 3,3Ј-diaminobenzidine. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Cytochrome P450 (P450)-derived epoxyeicosatrienoic acids (EETs) exert well recognized vasodilatory, diuretic, and tubular fluid-electrolyte transport actions that are predictive of a hypotensive effect. The study sought to determine the improvement of hypertension and cardiac function by overexpressing P450 epoxygenases in vivo. Long-term expression of CYP102 F87V or CYP2J2 in spontaneously hypertensive rats (SHR) was mediated by using a type 8 recombinant adeno-associated virus (rAAV8) vector. Hemodynamics was measured by a Millar Instruments, Inc. (Houston, TX) microtransducer catheter, and atrial natriuretic peptide (ANP) mRNA levels were tested by real-time polymerase chain reaction. Results showed that urinary excretion of 14,15-EET was increased at 2 and 6 months after injection with rAAV-CYP102 F87V and rAAV-CYP2J2 compared with controls (p < 0.05). During the course of the 6-month study, systolic blood pressure significantly decreased in P450 epoxygenase-treated rats, but the CYP2J2-specific inhibitor C26 blocked rAAV-CYP2J2-induced hypotension and the increase in EET production. Cardiac output was improved by P450 epoxygenase expression at 6 months (p < 0.05). Furthermore, cardiac collagen content was reduced in P450 epoxygenase-treated rats. ANP mRNA levels were up-regulated 6- to 14-fold in the myocardium, and ANP expression was significantly increased in both myocardium and plasma in P450 epoxygenase-treated rats. However, epidermal growth factor (EGF) receptor antagonist 4-(3'-chloroanilino)-6,7-dimethoxy-quinazoline (AG-1478) significantly attenuated the increase in the EET-induced expression of ANP in vitro. These data indicate that overexpression of P450 epoxygenases attenuates the development of hypertension and improves cardiac function in SHR, and that these effects may be mediated, at least in part, by ANP via activating EGF receptor.
    Journal of Pharmacology and Experimental Therapeutics 09/2010; 334(3):784-94. DOI:10.1124/jpet.110.167510 · 3.97 Impact Factor
  • Source
    • "Despite of that the common link between cardiac hypertrophy endothelial dysfunction, MAPK activation and cerebrovascular events still speculative [14]. Moreover, there is possible cross-talk between the mitogen-activated protein kinase (MAPK) and protein kinase C (PKCα) during the ISOinduced hypertrophic response [15] [16]. In addition, the target of both protein kinase A (PKA) and PKCα is thought to be the ras/ raf/MEK/ERK cascade in a variety of cell types [17] [18] [19] [20]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: To understand better the mediating role of ras/raf/ERK signaling pathway in development of cardiac hypertrophy and cerebrovascular events in vivo, the molecular mechanism of the pathway in heart and cerebral arteries after isoproterenol (ISO) induced beta-adrenergic receptor (betaAR) stimulation was examined in rabbit as animal model. Compared with the heart, our findings indicate that ISO-stimulation results in increase in mRNA levels of ras, raf, and immediate-early genes in the cerebral arteries. Conversely, the ras and raf protein expression levels (determined by Western blot) and the ras-GTP level (determined by pull-down assay) in the heart, but not the cerebral arteries, are markedly elevated after treatment. In addition, despite constant ERK1/2 abundance, phosphorylated ERK (pERK) activity was elevated at both sites with prominent effect on heart following stimulation. Opposing to the PKA and PKC, as upstream contributors in the pathway, which seem to be similarly affected at both sites following ISO-stimulation, the results imply that the downstream candidates ras and raf, as well as immediate-early genes, have different responses at both sites post-stimulation. The results provide an evidence of site-dependent differential response of ras/raf/ERK pathway after cardiac hypertrophy-induced by ISO-stimulation. This varied response may account for underlying mechanisms of development of cardiac hypertrophy and cerebrovascular events in heart and cerebral arteries, respectively.
    Biochimica et Biophysica Acta 11/2006; 1763(10):1067-75. DOI:10.1016/j.bbamcr.2006.08.002 · 4.66 Impact Factor
Show more